

ERIC QIONG WU, PH.D.
Managing Principal

Phone: (617) 425 8254
Fax: (617) 425 8001
ewu@analysisgroup.com

111 Huntington Avenue
Tenth Floor
Boston, MA 02199

Dr. Wu is a health economist specializing in health economics, outcomes, and market access issues related to pharmaceuticals and biologics. He has broad consulting experience to pharmaceutical and device companies, payers, and government agencies in North America, Europe, and Asia. Dr. Wu has extensive experience in the development of health economics and outcomes research strategy, analysis of medical claims and clinical trial data, patient chart review, patient surveys and physician surveys, and economic modeling to support treatment guideline development; global formulary and reimbursement submission; step therapy design; appropriate generics and biosimilars use; and investigations in comparative effectiveness, direct and indirect resource utilization and costs, work loss, quality of life, treatment pattern, disease prevalence, and adverse events. His interests also include developing new methods and statistical tests to address challenges in health care research. Dr. Wu is an adjunct professor at Nankai University in China and sits on the advisory board of the Health Economic Evaluation Center of the Chinese Physician Association. He also serves on the review committee for China's formulary drug user guidelines.

EMPLOYMENT

2002- present **Analysis Group, Inc.**
Boston, MA

EDUCATION

1998-2002 **Ph.D., University of Southern California**
Department of Pharmaceutical Economics and Policy
School of Pharmacy

2001-2002 **M.Sc., University of Southern California**
Masters Program in Regulatory Science (Regulation, Law, and
Management in Health Care and Pharmaceutical Industry)
School of Pharmacy

1998-2000 **M.A., University of Southern California**
Department of Economics
Successfully Completed the Ph.D. Core Theory Examinations for the
Department of Economics

1993-1997 **B.S., Peking University, Beijing, China**
Biochemistry and Molecular Biology Department
School of Life Sciences

PUBLICATIONS AND PRESENTATIONS

Journal Articles (Peer-reviewed Journals)

1. Yu AP, Bensimon AG, Marynchenko M, **Wu EQ**, Namjoshi M, Guo A, Ericson SG, Raje N. Comparison of Skeletal Complications and Treatment Patterns Associated with Early versus Delayed Zoledronic Acid Therapy in Multiple Myeloma. *Clinical Lymphoma, Myeloma & Leukemia* 2011, in press.
2. Signorovitch JE, **Wu EQ**, Swallow E, Kantor E, Fan L, Gruenberger J-B. Comparative Efficacy of Vildagliptin and Sitagliptin in Japanese Patients with Type 2 Diabetes: A Matching-Adjusted Indirect Comparison of Randomized Trials. *Clin Drug Investig*. 2011 in press.
3. Signorovitch JE, **Wu EQ**, Betts KA, Parikh K, Kantor E, Guo A, Bollu VK, Williams D, Wei LJ, DeAngelo DJ. Comparative Efficacy of Nilotinib and Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia: A Matching-Adjusted Indirect Comparison of Randomized Trials. *CMRO* 2011 in press.
4. Marynchenko M, Yu AP, Lauzon V, Ramakrishnan K, **Wu EQ**, Ben-Hamadi R, Blum S, Erder MH, Bose A. Economic Outcomes of Switching to another Generic SSRI, Escitalopram, or an SNRI among MDD patients treated with Generic SSRI therapy. *American Journal of Pharmacy Benefits*, forthcoming.
5. Yu AP, Yang H, **Wu EQ**, Juliana Setyawan J, Mocarski M, Blum S. Incremental Third-Party Costs Associated with COPD Exacerbations: a Retrospective Claims Analysis. *J Med Econ*, forthcoming.
6. Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, **Wu EQ**, Fan CP, Yu AP. Copayment Level, Treatment Persistence, and Health Care Utilization in Hypertension Patients Treated With Single-Pill Combination Therapy. *J Med Econ*. 2011 Mar 30. [Epub ahead of print]
7. Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, **Wu EQ**, Dworak H, Haim Erder M. Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. *Curr Med Res Opin*. 2011 Mar 28. [Epub ahead of print]
8. **Wu EQ**, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH. Economic Impact of Therapeutic Substitution of a Brand Selective Serotonin Reuptake Inhibitor with an Alternative Generic Selective Serotonin Reuptake Inhibitor in Patients with Major Depressive Disorder (April). *Ann Pharmacother*. 2011 Mar 17. [Epub ahead of print]
9. Velde NV, **Wu EQ**, Guo A, Lu M, Yu AP, Sharma H, Liu J, Fan CP, Shi L. The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population. *Prostate Cancer Prostatic Dis*. 2011 Mar;14(1):79-84. Epub 2010 Dec 21.
10. Chang J, Yang W, Kahler KH, Fellers T, Orloff J, Bensimon AG, Yu AP, Fan CP, **Wu EQ**. Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension. *Am J Cardiovasc Drugs*. 2011;11(1):21-32.
11. **Wu EQ**, Forsythe A, Guérin A, Yu AP, Latremouille-Viau D, Tsaneva M. Comorbidity Burden, Healthcare Resource Utilization, and Costs in Chronic Gout Patients Refractory to Conventional Urate-Lowering Therapy. *Am J Ther*. 2011 Feb 10. [Epub ahead of print]
12. Kimball AB, Bensimon AG, Guerin A, Yu AP, **Wu EQ**, Okun MM, Bao Y, Gupta SR, Mulani PM. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. *Am J Clin Dermatol*. 2011 Feb 1;12(1):51-62.

13. Pandya BJ, Bron M, McCall T, Yu AP, Chen KS, Mattson ME, **Wu EQ**. Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus. *Curr Med Res Opin*. 2011 Jan;27(1):189-95. Epub 2010 Dec 9.
14. **Wu EQ**, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. *Curr Med Res Opin*. 2010 Dec;26(12):2861-9. Epub 2010 Nov 9.
15. Reich K, Signorovitch J, Ramakrishnan K, Yu AP, **Wu EQ**, Gupta SR, Bao Y, Mulani PM. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial. *J Am Acad Dermatol*. 2010 Dec;63(6):1011-8. Epub 2010 Oct 8.
16. Chang J, Yang W, Fellers T, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, **Wu EQ**. Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement. *Curr Med Res Opin*. 2010 Sep;26(9):2203-12.
17. Cohen RD, Yu AP, **Wu EQ**, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. *Aliment Pharmacol Ther*. 2010 Apr;31(7):693-707.
18. Kimball AB, Guérin A, Tsaneva M, Yu AP, **Wu EQ**, Gupta SR, Bao Y, Mulani PM. Economic burden of comorbidities in patients with psoriasis is substantial. *J Eur Acad Dermatol Venereol*. 2011 Feb;25(2):157-163.
19. Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, **Wu EQ**, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy. *Aliment Pharmacol Ther*. 2010 Nov;32(10):1228-39. doi: 10.1111/j.1365-2036.2010.04466.x. Epub 2010 Sep 28.
20. Mease PJ, Signorovitch J, Yu AP, **Wu EQ**, Gupta SR, Bao Y, Mulani PM. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials. *Dermatology*. 2010;220(1):1-7. Epub 2009 Nov 19.
21. Menter A, Augustin M, Signorovitch J, Yu AP, **Wu EQ**, Gupta SR, Bao Y, Mulani P. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. *J Am Acad Dermatol*. 2010 May;62(5):812-8. Epub 2010 Mar 9.
22. Saurat JH, Guérin A, Yu AP, Latremouille-Viau D, **Wu EQ**, Gupta SR, Bao Y, Mulani PM. High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice. *Dermatology*. 2010;220(2):128-37.
23. Signorovitch J, Zhang J, **Wu EQ**, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH. Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension. *Curr Med Res Opin*. 2010 Apr;26(4):849-60.
24. Signorovitch JE, **Wu EQ**, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. *Pharmacoeconomics*. 2010 Oct 1;28(10).
25. **Wu EQ**, Ben-Hamadi R, Yu AP, Tang J, Haim Erder M, Bose A. Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons. *J Med Econ*. 2010 Jun;13(2):314-23.

26. Yang W, Chang J, Kahler KH, Fellers T, Orloff J, **Wu EQ**, Bensimon AG. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. *Curr Med Res Opin.* 2010;26:2065–2076.
27. Yu AP, Xie J, Bensimon A, Parikh K, **Wu EQ**, Ben-Hamadi R, Blum S, Erder HM. Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study. *J Med Econ.* 2010;13:599-609.
28. **Wu EQ**, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. *Curr Med Res Opin.* 2010 Jan; 26(1):61-9.
29. Nelson SP, Kothari S, **Wu EQ**, Beaulieu N, McHale JM, Dabbous OH. Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy. *J Med Econ.* 2009; 12(4):348-55.
30. Frois C, **Wu EQ**, Ray S, Colice GL. Inhaled Corticosteroids or Long-acting β -Agonists Alone or in Fixed-Dose Combinations in Asthma Treatment: A Systematic Review of Fluticasone/Budesonide and Formoterol/Salmeterol. *Clinical Therapeutics.* 2009 Dec; 31(12) 2779-99.
31. Kothari S, Nelson SP, **Wu EQ**, Beaulieu N, McHale JM, Dabbous OH. Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors. *Curr Med Res Opin.* 2009 Nov;25(11):2703-9.
32. Loftus EV Jr, Johnson SJ, Yu AP, **Wu EQ**, Chao J, Mulani PM. Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. *Eur J Gastroenterol Hepatol.* 2009 Nov;21(11):1302-9.
33. Yu AP, Tang J, Xie J, **Wu EQ**, Gupta SR, Bao Y, Mulani PM. Economic burden of psoriasis compared to the general population and stratified by disease severity. *Curr Med Res Opin.* 2009 Oct;25(10):2429-38.
34. Chey WD, Mody RR, **Wu EQ**, Chen L, Kothari S, Persson B, Beaulieu N, Lu M. Treatment patterns and symptom control in patients with GERD: US community-based survey. *Curr Med Res Opin.* 2009;25(8):1869-78.
35. **Wu EQ**, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E. Frequency, Risk, and Cost of Gout-related Episodes Among the Elderly: Does Serum Uric Acid Level Matter?. *J Rheumatol.* 2009; 36(5): 1032-40.
36. Menter A, Augustin M, Signorovitch J, Yu AP, **Wu EQ**, Gupta SR, Bao Y, Mulani P, The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis in a randomized clinical trial. *Journal of American Academy of Dermatology (JAAD).* In press.
37. **Wu EQ**, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH. Treatment Persistence, Healthcare Utilization and Costs in Adult Patients with Major Depressive Disorder: A Comparison between Escitalopram and Other SSRI/SNRIs. *Journal of Medical Economics.* *J Med Econ.* 2009;12(2):124-35.
38. Birnbaum H, Greenberg P, Tang J, Hsieh M, **Wu EQ**, Amand C, Ben-Hamadi R. Antidepressant treatment patterns and costs among US employees. *Journal of Medical Economics,* 2009; 12(1): 36-45.
39. Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, **Wu EQ**, Chao J, Mulani PM. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. *PharmacoEconomics.* 2009;27(7):609-21.
40. Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, **Wu EQ**, Pollack PF, Lomax KG, Chao J, Mulani PM. Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results from the CHARM Trial. *Am J Gastroenterol.* 2009;104(5):1170-9.

41. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV Jr, Lomax KG, Yu AP, **Wu EQ**, Chao J, Mulani P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. *Gastroenterology*. 2008 Nov;135(5):1493-9.
42. **Wu EQ**, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK. Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population. *Curr Med Res Opin*. 2008 Dec;24(12):3493-501.
43. Loftus EV, Feagan BG, Colombel JF, Rubin DT, **Wu EQ**, Yu AP, Pollack PF, Chao J, Mulani P. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. *Am J Gastroenterol*. 2008 Dec;103(12):3132-41
44. **Wu EQ**, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder MH. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants. *Curr Med Res Opin*. 2008 Oct;24(10):2805-13.
45. **Wu EQ**, Greenberg PE, Yang E, Yu A, Erder MH. Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. *Curr Med Res Opin*. 2008 Sep;24(9):2587-95.
46. Xie J, **Wu EQ**, Zheng ZJ, Sullivan PW, Zhan L, Labarthe DR. Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences. *Circulation*. 2008 Jul 29;118(5):491-7.
47. **Wu EQ**, Chen L, Birnbaum H, Yang E, Cifaldi M. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. *Curr Med Res Opin*. 2008 Aug;24(8):2229-40.
48. **Wu EQ**, Mulani PM, Yu AP, Tang J, Pollack PF. Loss of Treatment Response to Infliximab Maintenance Therapy in Crohn's Disease: A Payer Perspective. *Value Health*. 2008 Sep-Oct; 11(5): 820-9.
49. **Wu EQ**, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E. Disease-Related and Total Health Care Costs of Gout Patients of Elderly Patients with Gout. *Journal of Managed Care Pharmacy*. 2008 March;14(2):164-175
50. Yu AP, Cabanilla LA, **Wu EQ**, Mulani PM, Chao J. The costs of Crohn's disease in the United States and other Western countries: a systematic review. *Curr Med Res Opin*. 2008;24(2):319-28.
51. **Wu EQ**, Yu AP, Tang J, Atanasov PD, Chao J, Mulani PM. Impact of Sustained Remission and Clinical Response on the Risk of Hospitalization in Patients With Crohn's Disease. *Managed Care Interface*, 2008.
52. **Wu EQ**, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S. Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France. *Curr Med Res Opin*. 2007 Sep;23(9):2035-42.
53. **Wu EQ**, Persson B, Beaulieu N, White L, Spalding J, Mahmarian JJ. Impact of Single-Photon Emission Computed Tomography (SPECT) Use After Acute Myocardial Infarction (AMI) on Cardiac Procedure Rates and Hospital Length of Stay. *Journal of Nuclear Cardiology*. 2007;14(4):S115.
54. Sullivan PW, Ghushchyan V, Wyatt HR, **Wu EQ**, Hill JO. Productivity Costs Associated with Cardiometabolic Risk Factor Clusters in the United States. *Value in Health*. 2007;10(6):443-50.
55. **Wu EQ**, Mulani P, Farrell, Sleep D. Mapping FACT-P and EORTC QLQ-C30 to the EQ-5D Health Utility in Metastatic Hormone-Refractory Prostate Cancer Patients. *Value in Health*. 2007;10(5):408-14.

56. **Wu EQ**, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D. Health Care Costs of Adults Treated for Attention-Deficit/Hyperactivity Disorder Who Received Alternative Drug Therapies. *Journal of Managed Care Pharmacy*. 2007;13(7):561-9.
57. Colice G, **Wu EQ**, Birnbaum HG, Daher M, Marynchenko MB. Use of Inhaled Corticosteroids and Healthcare Costs in Mild Persistent Asthma, *Journal of Asthma*. 2007;44(6):479-83.
58. Shi L, **Wu EQ**, Hodges M, Yu AP, Birnbaum HG. Retrospective economic and outcomes analyses using non-US databases: a review. *PharmacoEconomics*. 2007;25(7):563-76.
59. Sullivan PW, Ghushchyan V, Wyatt HR, **Wu EQ**, Hill JO. The impact of cardiometabolic risk factor clusters on health-related quality of life in the US. *Obesity*. 2007;15(2):511-21.
60. Yu AP, **Wu EQ**, Birnbaum HG, Emami S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A. Short Term Economic Impact of Body Weight Change among Patients with Type 2 Diabetes Treated with Antidiabetic Agents. *Curr Med Res Opin*. 2007;23(9):2157-69.
61. **Wu EQ**, Chen L, Birnbaum HG, Yang E, and Cifaldi M. Costs of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy. *Curr Med Res Opin*. 2007;23(8):1749-59.
62. **Wu EQ**, Shi L, Birnbaum HG, Hudson T, Kessler RC. Annual Prevalence of Diagnosed Schizophrenia in the United States: A Claims Data Analysis Approach. *Psychological Medicine*. 2006;36(11):1535-40.
63. **Wu EQ**, Birnbaum HG, Cifaldi M, Kang Y, Mallet D, Colice G. Development of a COPD Severity Score. *Current Medical Research and Opinion*. 2006;22(9):1679-87.
64. **Wu EQ**, Birnbaum HG, Mareva MN, Kim Le T, Robinson RL, Rosen A, Gelwicks S. Cost-Effectiveness of Duloxetine versus Routine Treatment for U.S. Patients With Diabetic Peripheral Neuropathic Pain. *The Journal of Pain*. 2006;7(6):399-407.
65. **Wu EQ**, Birnbaum HG, Mareva M, Parece A, Huang Z, Mallett D, Taitel H. Interstitial Cystitis (IC) Cost, Treatment And Comorbidities In An Employed Population. *PharmacoEconomics*. 2006;24(1):55-65.
66. **Wu EQ**, Ben-Hamadi R, Birnbaum HG, Farrell MH, Spalding J, Stang P, Hartmann KE. Lifetime Costs of Patients with Clinically-Detected Uterine Fibroids: An Employer's Perspective. *Drug Benefit Trends*. 2006;18(7):405-10.
67. **Wu EQ**, Birnbaum HG, Kang Y, Parece A, Mallett D, Taitel H, Evans RJ. A Retrospective Claims Database Analysis to Assess Patterns of Interstitial Cystitis (IC) Diagnosis. *Current Medical Research and Opinion*. 2006;22(3):495-500.
68. Xie J, **Wu EQ**, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR. Impact of stroke on health-related quality of life in the United States. *Stroke*. 2006;37(10):2567-72.
69. Hartmann KE, Birnbaum HG, Ben-Hamadi R, **Wu EQ**, Farrell MH, Spalding J, Stang P. Annual costs associated with diagnosis of uterine leiomyomata. *Obstetrics & Gynecology*. 2006;108(4):930-7.
70. Colice G, **Wu EQ**, Birnbaum HG, Daher M, Marynchenko MB, Faruqi R, Varghese S. Health Care and Work Loss Costs Associated with Persistent Asthma Patients in a Privately Insured Population. *Journal of Occupational and Environmental Medicine*. 2006;48(8):794-802.
71. **Wu EQ**, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. The Economic Burden of Schizophrenia in the United States in 2002. *Journal of Clinical Psychiatry*. 2005;66(9):1122-29.
72. **Wu EQ**, Birnbaum HG, Marynchenko M, Mareva M, Williamson T, Mallett D. Employees With Overactive Bladder: Work Loss Burden. *Journal of Occupational and Environmental Medicine*. 2005; 47(5):439-46.

73. **Wu EQ**, Birnbaum HG, Mareva M, Edward Tuttle, Jackman W, Ruskin J. Economic Burden and Comorbidities of Atrial Fibrillation in an Employed Population. *Curr Med Res Opin.* 2005;21(10):1693-99.
74. Kessler RC, Birnbaum HG, Demler O, Falloon IR, Gagnon E, Guyer M, Howes M, Kendler KS, Shi L, Walters EE, **Wu EQ**. The Prevalence and Correlates of Non-Affective Psychosis in the National Comorbidity Survey Replication. *Biological Psychiatry.* 2005; 58:668-76.

Book Chapter

Liu G, Cai R, Chao S, Xiong X, Zhao Z, **Wu EQ**, China's urban health insurance reform experiment in Zhenjiang: cost and utilization analyses, *The Economics of Health Care in Asia-Pacific Countries*, Edward Elgar Publishing Limited, 2002.

Selected Conference Presentations

1. Signorovitch J, **Wu EQ**, We LJ. Comparative effectiveness research for personalized medicine. Workshop at ISPOR 15th Annual International Meeting, Atlanta, GA, USA, October 15-19, 2010.
2. **Wu EQ**, Yu DZ, Xie J, Gu RM. Selecting the optimal target population for formulary coverage. Workshop at ISPOR 4th Asia-Pacific Conference, Phuket, Thailand, September 5-7, 2010.
3. Menter A, Signorovitch J, Parikh K, Yu AP, **Wu EQ**, Yoo S, Gu Y, Valdes J, Sundaram M, Bao Y, Mulani P. ABT-874 Versus Etanercept or Placebo Treatment for Moderate to Severe Psoriasis: Health-Related Quality of Life.
4. Kimball AB, Signorovitch J, Farooqui S, Yu AP, **Wu EQ**, Gupta SR, Bao Y, Mulani PM. Longer disease duration of psoriasis with hand/foot involvement is independently associated with persistent impairment of work productivity and activity. Poster accepted for oral presentation at the 19th Congress of the EADV - Gothenburg, Sweden, 6-10 October 2010.
5. Menter A, Guérin A, Yang H, **Wu EQ**, Yu AP, Gupta SR, Goldblum O, Bao Y, Mulani PM. Adalimumab Provides Health-Related Quality-of-Life Benefits for Patients With Psoriasis With Suboptimal Response to Etanercept Methotrexate, or Phototherapy. Poster accepted for oral presentation at the 19th Congress of the EADV - Gothenburg, Sweden, 6-10 October 2010.
6. Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, **Wu EQ**, Setyawan J, Dembiski M, Blum S. Persistence and Adherence in Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Multiple- versus Single-Long Acting Inhaler. To be presented at Chest 2010, Vancouver, BC, Canada, October 30-November 4, 2010.
7. Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, **Wu EQ**, Setyawan J, Dembiski M, Blum S. Risk of Exacerbations among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Multiple-versus Single-Long Acting Inhalers. To be presented at Chest 2010, Vancouver, BC, Canada, October 30-November 4, 2010.
8. Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, **Wu EQ**, Setyawan J, Dembiski M, Blum S. Resource Utilization and Costs in Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Multiple-versus Single-Long Acting Inhalers. To be presented at Chest 2010, Vancouver, BC, Canada, October 30-November 4, 2010.
9. Guérin A, Bollu V, Guo A, Griffin JD, Yu AP, **Wu EQ**. Comparison of Adherence between Nilotinib and Dasatinib as Second-Line Therapies In Chronic Myeloid Leukemia. Accepted for poster presentation at the 2010 Annual Meeting of the American Society of Hematology, Orlando, FL, USA.
10. Bron M, Yu A, Marynchenko M, Sun SX, Yang H, **Wu EQ**. Total and diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs from a large us

- managed care cohort. Presented at ISPOR 4th Asia-Pacific Conference, Phuket, Thailand, September 5-7, 2010.
11. Bron M, Yu AP, Marynchenko M, Sun SX, Yang H, **Wu EQ**. Diabetes-Related Costs Associated with Hypoglycemia in Type 2 Diabetes Mellitus Patients Initiated on Oral Antidiabetic Drugs. Poster presented at Academy of Managed Care Pharmacy, 22nd Annual Meeting & Showcase San Diego, CA, April 7-10, 2010.
 12. Chang JR, Yang W, Kahler KH, Fellers TS, Orloff J, Bensimon AG, Yu AP, Fan CS, **Wu EQ**. Aliskiren combined with Angiotensin II-receptor blockers (ARB) resulted in better outcomes compared to arb combined with angiotensin-converting enzyme inhibitors (ACEI): Results from a claims database analysis. Presented at the International Society for Pharmacoeconomics & Outcomes Research 15th Annual International Meeting, Atlanta, GA, May 2010.
 13. **Wu EQ**, Guo A, Shi L, Lu M, Yu AP, Sharma H., Fan CPS, Vander Velde N. Comparing Early Intervention with Zoledronic Acid to No Bisphosphonate (BP) Therapy in Patients with Metastatic Prostate Cancer to Bone: A Study of the US Veterans Affairs (VA) Population. Presented at the CABS 10th International Meeting, Sept 22-25, 2010, Sheffield, UK.
 14. **Wu EQ**, Guérin A, Latremouille-Viau D, Yu AP, Cloutier M, Gupta SR, Bao Y, Mulani PM. Resource utilization and costs in patients with moderate to severe psoriasis treated with adalimumab or etanercept in a real-world setting. Poster accepted for oral presentation at the 19th Congress of the EADV - Gothenburg, Sweden, 6-10 October 2010.
 15. **Wu EQ**, Guérin A , Bollu V, Williams D, Guo A, Ponce de Leon D, Yu AP, Quintas-Cardama A. The Economic Burden of Pleural Effusions (PE) in Patients with Chronic Myeloid Leukemia (CML). Accepted for poster presentation at the 2010 Annual Meeting of the American Society of Hematology, Orlando, FL, USA.
 16. Guérin A, Bollu V, Guo A, **Wu EQ**, Yu AP, Sirulnik LA, Griffin JD. Non-adherence to imatinib in chronic myeloid leukemia (CML) patients is associated with short- and long-term negative impacts on health care resource utilization and costs. Presented at the ISPOR 15th Annual International Meeting, Atlanta, GA, USA, October 15-19, 2010.
 17. Signorovitch J, Latrémouille-Viau D, Dea K, **Wu EQ**, Zhang J. Comparison of drug costs and clinical outcomes with tobramycin solution for inhalation and aztreonam lysine for inhalation in cystic fibrosis. To be presented at 24th North American Cystic Fibrosis Conference, Baltimore, Maryland, USA, October 21-23, 2010.
 18. Papp K, **Wu EQ**, Goldblum OM, Gupta SR. AAD 2010: Fatigue Outcomes Following Withdrawal from and Retreatment with Adalimumab Among Patients Maintained on Adalimumab for Moderate to Severe Psoriasis. Presented Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, LA, USA, February 4-8, 2010.
 19. Papp K, Guérin A , Parikh K, Signorovitch J, Yu AP, **Wu EQ**, Okun M, Gupta SR, Bao Y, PM. Benefit-risk analysis of adalimumab for patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy. Poster accepted for oral presentation at the 19th Congress of the EADV - Gothenburg, Sweden, 6-10 October 2010.
 20. Papp K, Signorovitch J, Parikh K, Yu AP, **Wu EQ**, Yoo S, Gu Y, Williams D, Valdes J, Sundaram M, Bao Y, Mulani P. Psoriasis Treatment With ABT-874: Effects on Health-Related Quality of Life and Work Productivity and Activity Impairment. Poster accepted for oral presentation at the 19th Congress of the EADV - Gothenburg, Sweden, 6-10 October 2010.
 21. Duffin KC, Guérin A , Yang H, **Wu EQ**, Yu AP, Gupta SR, Goldblum O, Bao Y, Mulani PM. Adalimumab improves sleep symptoms in patients with psoriasis with suboptimal response to etanercept,

- methotrexate, or phototherapy. Poster accepted for oral presentation at the 19th Congress of the EADV - Gothenburg, Sweden, 6-10 October 2010.
22. Sawicki G, Signorovitch J, Latremouille-Viau D, Wartburg M, **Wu EQ**, Zhang J, Shi LZ. Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis. Accepted for presentation at 24th North American Cystic Fibrosis Conference, Baltimore, Maryland, USA, October 21-23, 2010.
 23. Signorovitch J, Samuelson T, Ramakrishnan K, Marynchenko M, Blum SI, Ramasamy A, **Wu EQ**. Persistence with Nebivolol Compared to Other β -Blockers in the Treatment of Hypertension: a Retrospective Claims Analysis. American Heart Association, High Blood Pressure Research Conference 2010 Scientific Sessions Washington, DC, October 13-16, 2010.
 24. **Wu EQ**, Bollu V, Guo A, Guérin A, Tsaneva M, Williams D, Griffin JD. Comparison of healthcare resource utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia (CML). Presented at the ISPOR 15th Annual International Meeting, Atlanta, GA, USA, October 15-19, 2010.
 25. **Wu EQ**, Guérin A, Lyon-Caen S, Latremouille-Viau D, Yu AP, Gupta SR, Bao Y. Associated Resource Utilization and Costs of Patients with Psoriasis Switching from Etanercept to Adalimumab versus Dose Escalating with Etanercept. Presented Poster accepted for oral presentation at American Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, LA, USA, February 4-8, 2010.
 26. **Wu EQ**, Latremouille-Viau D, Guérin A, Cloutier M, Yu AP, Gupta SR, Bao Y. Healthcare Outcomes Associated with the Continuous Use of Adalimumab versus the Continuous and Intermittent Use of Etanercept in Patients with Psoriasis. Presented Poster accepted for oral presentation at American Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, LA, USA, February 4-8, 2010.
 27. **Wu EQ**, Signorovitch JE, Bao Y, Mulani PM. Comparative Effectiveness of Adalimumab versus Ustekinumab Treatment for Psoriasis: Clinical Efficacy, Safety and Cost per Responder. Presented at American Academy of Dermatology (AAD) 68th Annual Meeting, Miami Beach, Florida, USA, March 5-9, 2010.
 28. **Wu EQ**, Signorovitch JE, Yu AP, Latremouille-Viau D, Zhang J, Dastani H, Kahler KH. Economic Impact of Switching from Valsartan to Other Angiotensin II Receptor Blockers (ARBs) in Patients with Hypertension. Presented at the AMCP 2009 Educational Conference, San Antonio, Texas, October 7-9, 2009.
 29. Yang W, Chang J, Kahler KH, Fellers T, Orloff J, **Wu EQ**, Bensimon AG, Yu AP, Fan CS. Compliance and healthcare utilization among patients with hypertension treated with single pill combination vs. free combination antihypertensive therapy: U.S. national and state level results from a claims database analysis. Presented at the International Society for Pharmacoeconomics & Outcomes Research 15th Annual International Meeting, Atlanta, GA, May 2010.
 30. Yim YM, Yu E, Yu AP, Yang H, **Wu EQ**. Healthcare Costs of Second-line (2L) Metastatic Colorectal Cancer (mCRC) Patients Treated with Bevacizumab (BV) versus Cetuximab (CX). To be presented at 35th ESMO Congress, Milan, Italy, 8-12 October 2010.
 31. Remission of Major Depressive Disorder without Adverse Events: A Comparison of Escitalopram and Serotonin Norepinephrine Reuptake Inhibitors, U.S. Psychiatric & Mental Health Congress, 2009.
 32. Economic Impact of Switching from Valsartan to Other Angiotensin II Receptor Blockers (ARBs) for Non-Medical Reasons in Patients with Hypertension, AMCP's 2009 Educational Conference.
 33. The Economic Outcomes of Early Initiation with Second Generation Antidepressants among Adolescents With Depression, AMCP's 2009 Educational Conference.

34. Economic Consequence of Switching to Citalopram after its Generic Entry Among Major Depressive Disorder (MDD) Patients Treated With Escitalopram, AMCP's 2009 Educational Conference.
35. Comparative Effectiveness without Head- To- Head Trials: Indirect Comparisons Using Primary and Published Clinical Trial Data, Ispor Workshop, ISPOR, 2009.
36. Comparison of Hospitalizations and Health Care Costs of Elderly Major Depressive Disorder (MDD) Patients Treated With Escitalopram, Generic SSRIs, Or SNRIs, ISPOR, 2009.
37. The Economic Impact of Generic Switching For Patients with Major Depressive Disorder (MDD) Treated With Escitalopram Or A Patented SSRI, ISPOR, 2009.
38. Economic Assessment of Second-line Treatment: Switching from a Generic SSRI to Escitalopram, an SNRI, or Another Generic SSRI for Patients with Major Depressive Disorder (MDD), ISPOR, 2009.
39. Healthcare Resource Utilization Associated with Escalating Imatinib versus Switching to Dasatinib in Patients with Chronic Myelogenous Leukemia, ISPOR, 2009.
40. Number-Needed-to-Treat (NNT) Analysis: Remission Rates for adalimumab vs. Infliximab in Crohn's Disease, ISPOR, 2009.
41. Economic Implication of Dose Escalation in Depressed Patients Treated with Escitalopram or Venlafaxine XR, ISPOR, 2009.
42. Young Patients with Crohn's Disease Are at Increased Risk for Psychiatric Disorders, European Crohn's & Colitis Organisation 4th Congress, 2009.
43. Discontinuation of Adalimumab Treatment for Psoriasis Following Sustained Response: Effects on Health-Related Quality of Life, American Academy of Dermatology Annual meeting, 2009.
44. Adalimumab's Benefits for Patient-Reported Outcomes in Psoriasis Patients Are Consistent Across Subgroups With Different Disease Histories, American Academy of Dermatology Annual meeting, 2009.
45. Real world treatment patterns of gastrointestinal stromal tumor patients, American Society of Clinical Oncology Annual meeting, 2009.
46. Adverse Events Associated with Imatinib Dose Escalation versus Switching to Dasatinib in Patients with Chronic Myelogenous Leukemia, American Society of Clinical Oncology Annual meeting, 2009.
47. Treatment Patterns of Chronic Myelogenous Leukemia Patients who Initiated their Treatment on Imatinib, American Society of Clinical Oncology Annual meeting, 2009.
48. Increased Risk of Psychiatric Disorders in Young Patients with Crohn's Disease, Digestive Disease Week (DDW) Annual conference, 2009.
49. Increased Risk of Clinical Relapse Is Associated with Longer Disease Duration in Crohn's Disease, Digestive Disease Week (DDW) Annual conference, 2009.
50. Treatment Compliance and Health Care Costs of Medicaid Depressed Adult Patients Treated with Escitalopram versus Citalopram, ECNP 21st Congress, 2008.
51. Adalimumab Treatment Significantly Reduces Hospitalization Risk for TNF-Antagonist-Naïve Patients with Crohn's Disease. American College of Gastroenterology 2008 Annual meeting, Orlando, Canada.
52. Health-Related Quality Of Life in TNF-Antagonist-Naïve Patients with Crohn's Disease During Short-And Long-Term Adalimumab Treatment. American College of Gastroenterology 2008 Annual meeting, Orlando, Canada.

53. Infliximab Dosage-Increase Rate in Patients With Crohn's Disease, American College of Gastroenterology 2008 Annual meeting, Orlando, Canada.
54. Achieving glycemic goal with initial combination therapy versus sequential augmentation therapy using metformin and pioglitazone. 44th EASD meeting, 2008. Italy.
55. Health Care Utilization and Costs of Depressed Patients Treated with Escitalopram versus SNRIs, ECNP 21st Congress, 2008.
56. Health Care Resource Utilization and Costs Comparison For MDD Patients on 10mg Escitalopram Who Increased to 20mg Dose vs. Those Who Were Switched to SNRI, ISPOR 13th Annual International Meeting, 2008.
57. Comparative Glycemic Goal Achievement among Type 2 Diabetes Mellitus Patients Treated with Oral Antidiabetic Monotherapies, American Diabetes Association's 68th Scientific Sessions, 2008.
58. Adherence to Infliximab Maintenance Therapy and Its Impact on Hospitalization of Patients with Crohn's Disease, ISPOR 13th Annual International Meeting, 2008.
59. Are Proton Pump Inhibitors (PPIs) Sufficient in Controlling Symptoms of Gastro-Esophageal Reflux Disease (GERD)? - A Community-Based US Survey Study, Digestive Disease Week (DDW), 2008.
60. Nighttime Symptoms and Sleep Impairment among Patients with Gastro-Esophageal Reflux Disease (GERD) Receiving Prescription (Rx) Proton Pump Inhibitors (PPIs), Digestive Disease Week (DDW), 2008.
61. Stress Single-Photon Emission Computed Tomography Reduces Total Direct Medical Costs and Rates of Utilization After Acute Myocardial Infarction, American College of Cardiology (ACC) 57th Annual Scientific Session, 2008.
62. Clinical and Economic Outcomes among Women Using Levonorgestrel-Releasing Intrauterine System (LNG-IUS), ISPOR 13th Annual International Meeting, 2008.
63. Impact of Switching to Another SSRI for Non-Medical Reasons on Health Care Utilization and Costs Among MDD Patients Initiated with Escitalopram, APA, 2008.
64. **Wu EQ**, Greenberg P, Erder MH. Assessing Step Therapy/Generic Switching: Clinical and Economic implications of Acquisition Costs vs. Total Health Care Costs Paradigm, Congressional Budget Office, 2008.
65. Nelson SP, Kothari S, **Wu EQ**, Persson B, Beaulieu N, Arana M, Lu M. Healthcare Utilization and Cost in Pediatric Gastroesophageal Reflux Disease (GERD) Patients on Continuous vs. Intermittent Proton Pump Inhibitor (PPI) Treatment Regimens, American College of Gastroenterology (ACG), 2007.
66. **Wu EQ**, Feng W, Johnson S, Beaulieu N, Cremieux P, Cortes J. Medical Costs Associated with Imatinib Non-compliance in Chronic Myeloid Leukemia Patients, Journal of Clinical Oncology, 2007 ASCO Annual Meeting.
67. Nelson SP, Kothari S, **Wu EQ**, Persson B, Beaulieu N, Arana M, Orenstein SR, El-Serag H. Differences in Health Care Visits Coded for Potential Proxy Conditions/Symptoms of Gastroesophageal Reflux Disease (GERD) before and after a GERD Diagnosis: A Pediatric Database Study, American College of Gastroenterology (ACG), 2007.
68. **Wu EQ**, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R. Healthcare Cost of Gout in an Elderly Population: A Claims Database Analysis, American Geriatrics Society (AGS), 2007.

69. **Wu EQ**, Yang E, Greenberg P, Erder MH, Buessing M. Comparing Treatment Compliance, Hospitalization, and Costs of Elderly MDD Patients on Escitalopram and Citalopram, International Health Economics Association, 2007.
70. **Wu EQ**, Yang E, Greenberg P, Erder MH, Yu A, Buessing M. Health care costs and resource use in patients with major depressive disorder: a comparison between escitalopram and other antidepressants (SSRI/SNRI), International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2007.
71. **Wu EQ**, Yang E, Greenberg P, Erder MH, Buessing M. Comparison of Health Care Costs and Hospitalization Days of Elderly Major Depressive Disorder Patients Treated with Escitalopram and Other Antidepressants, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2007.
72. **Wu EQ**, Yang E, Greenberg P, Erder MH, Buessing M. Comparing Treatment Compliance and Hospitalization of Elderly MDD Patients on Escitalopram and Other SSRI/SNRIs, New Clinical Drug Evaluation Unit (NCDEU), 2007.
73. **Wu EQ**, Yang E, Greenberg P, Erder MH, Buessing M. Comparing Treatment Compliance, Hospitalizations, and Costs of Elderly MDD Patients on Escitalopram and Citalopram, Institute on Psychiatric Services (APA-I), 2007.
74. **Wu EQ**, Yang E, Greenberg P, Erder MH, Buessing M. Treatment Compliance of Adult Depressed Patients on Escitalopram and Citalopram, European College of Neuropsychopharmacology (ECNP), 2007.
75. **Wu EQ**, Yu AP, Tang J, Atanasov PD, Chao J, Mulani PM. Lower Disease Activity And Clinical Remission Are Associated With Reduced Hospitalization Risk In Crohn's Disease, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2007.
76. Colombel JF, Sandborn WJ, Rutgeerts P, Yu A, **Wu EQ**, Pollack PF, Chao J, Mulani P. Continuous vs. Induction Only/Reinitiated Adalimumab Maintenance Therapy Yields Optimal Results for Moderate to Severe Crohn's Disease: Sub-analysis of CHARM, American College of Gastroenterology, 2007.
77. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, **Wu EQ**, Mulani PM. An Evaluation of Adalimumab on the Risk of Hospitalization in Patients with Crohn's Disease, Data from CHARM, DDW 2007.
78. Loftus EV, **Wu EQ**, Yu AP. Impact of adalimumab (HUMIRA (R)) on patient-reported outcomes, American College of Gastroenterology, 2007.
79. Colombel JF, **Wu EQ**, Yu AP. Impact of adalimumab (HUMIRA (R)) on patient-reported outcomes among patients with fistulizing Crohn's disease in the CHARM trial, American Journal of Gastroenterology, 2007.
80. **Wu EQ**, Patel P, Krishnan E, Yu AP. Treatment Cost of Gout in an Elderly Population: A Claims Database Analysis, American Geriatrics Society, 2007.
81. **Wu EQ**, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R. Cost and Risk of Gout Flares among the Elderly: Does Serum Uric Acid Level Matter?. American Geriatrics Society (AGS), 2007.
82. Navarro R, **Wu EQ**. Health Economics Impact in the Treatment of Depression. National Association of Managed Care Physicians (NAMCP), 2007.
83. **Wu EQ**, Persson B, Beaulieu N, White L, Spalding J, Mahmarian JJ. Impact of Single-Photon Emission Computed Tomography (SPECT) Use after Acute Myocardial Infarction (AMI) on Cardiac Procedures Rates and Hospital Length of Stay, American Society of Nuclear Cardiology (ASNC), 2007.

84. **Wu EQ**, Elaine Y, Greenberg P, Erder M.H., Yu A, Buessing M. Comparing Treatment Compliance and Hospitalization of Elderly MDD Patients on Escitalopram and Other SSRI/SNRIS, National Clinical Drug Evaluation Unit (NCDEU), 2007.
85. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Lomax KG, **Wu EQ**, Mulani PM. An Evaluation of Adalimumab on the Risk of Hospitalization in Patients with Crohn's Disease, Data from CHARM (318139), Digestive Disease Week (DDW), 2007.
86. Birnbaum H, Greenberg P, Tang J, Hsieh M, **Wu EQ**, Reygrobellet C, Ben-Hamadi R. Antidepressant Treatment Patterns and Related Costs among U.S. Employees, American Psychiatric Association (APA), 2007.
87. **Wu EQ**, Yang E, Greenberg P, Erder MH, Yu A, Buessing M. Comparison of Health Care Costs and Hospitalization Days of Elderly Major Depressive Disorder Patients Treated with Escitalopram and Other Antidepressants, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2007.
88. **Wu EQ**, Yang E, Greenberg P, Erder MH, Buessing M. Comparing Treatment Compliance, Hospitalization, and Cost of Elderly MDD Patients on Escitalopram and Citalopram, International Health Economics Association (iHEA), 2007.
89. **Wu EQ**, Mody R, Krishnan E, Yu AP, Cahill K, Tang J, Patel P. Tighter Control of Serum Uric Acid in Gout is Associated with Lower Morbidity and Health Care Costs, November, 2006.
90. **Wu EQ**, Yu A, Tang J, Yermakov S, Naeem A, Beaulieu N, Mulani P. Loss of treatment response among Crohn's disease patients receiving infliximab maintenance therapy, Academy of Managed Care Pharmacy, 2006.
91. **Wu EQ**, Borton J, Kahn E, Said G, T.K. Le, Garcia-Cebrian A, Monz B. Prevalence of Diabetic Peripheral Neuropathy and Associated Pain in French Adults, European Neurological Society, 2006.
92. **Wu EQ**, Birnbaum H, Zhang HF, Radeva R, Yang E, Castor A. Medical Costs and Hospitalization of Adults Diagnosed with Attention-Deficit/Hyperactivity Disorder Who Received Alternative Therapies, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2006.
93. **Wu EQ**, Xie J, Sullivan PW. Adult Economic Status and Obesity in the United States: 2000 – 2002, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2006.
94. **Wu EQ**, Xie J, Hill JO, Wyatt H, Sullivan PW. Obesity and Quality of Life in the United States: 2000 – 2002, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2006.
95. **Wu EQ**, Mulani P, Farrell MH, Sleep D. Mapping FACT-P and EORTC QLQ-C30 to the EQ-5d Health Utility in Metastatic Hormone-Refractory Prostate Cancer Patients, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2006.
96. **Wu EQ**, Birnbaum H, Ben-Hamadi R, Yu A, Tang J, Greenberg P, Gilloteau I, Smadja E. Annual Costs Associated with Patterns of Antidepressant Treatment Response among Employees, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2006.
97. **Wu EQ**, Yu AP, Birnbaum H, Emani S, Fay M, Oglesby A, Pohl G, Stockl K, Wintle M, Yang E. Short Term Economic Impact of Weight Change among Patients with Type 2 Diabetes, American Diabetes Association (ADA), 2006.
98. Yu AP, **Wu EQ**, Birnbaum H, Emani S, Fay M, Oglesby A, Pohl G, Stockl K, Wintle M. Glycemic Control, Hypoglycemic Therapy and Subsequent Weight Change among Type 2 Diabetes Patients, American Diabetes Association (ADA), 2006.

99. **Wu EQ**, Birnbaum H, Ben-Hamadi R, Tang J, Greenberg P, Gilloteau I, Smadja E. Patterns of Antidepressant Treatment Response in an Employed Population, American Psychiatric Association (APA) Annual Meeting, 2006.
100. **Wu EQ**, Birnbaum H, Zhang HF, MD, Radeva J, Yang E, Castor A. Employer Burden for Adults Diagnosed with Attention-Deficit/Hyperactivity Disorder Who Received Alternative Therapies, American Psychiatric Association (APA), 2006.
101. Colice G, Crivera C, **Wu EQ**, Birnbaum HG, Daher M, Marynchenko MB, Faruqi R, Varghese ST. Inpatient and Emergency Department Utilization of Persistent Asthma Patients, American Thoracic Society (ATS), 2006.
102. **Wu EQ**, Birnbaum H, Farrell MH, Spalding J, Stang P, Hartmann KE. Lifetime Costs of Patients with Clinically-Detected Uterine Fibroids: An Employer Perspective, The American College of Obstetricians and Gynecologists (ACOG), 2006.
103. Hartmann KE, Birnbaum H, **Wu EQ**, Ben-Hamadi R, Spalding J, Stang P. Annual Costs Associated with Diagnosis of Uterine Fibroids, The American College of Obstetricians and Gynecologists (ACOG), 2006.
104. Cremieux P, Xie J, **Wu EQ**, Castor A. Health-Related Quality Of Life of Anemia Patients in the U.S., International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia-Pacific, 2006.
105. Cremieux P, Xie J, Greenberg P, **Wu EQ**, Castor A. Obesity's Impact on Diabetes Patients' Health-Related Quality Of Life In The U.S., International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia-Pacific, 2006.
106. Xie J, **Wu EQ**, Zheng ZJ, Croft JB, Mensah GA, Labarthe D. Health-Related Quality Of Life of Stroke Survivors in the U.S., International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia-Pacific, 2006.
107. **Wu EQ**, Xie J, Hill JO, Wyatt H, Sullivan PW. Quality of Life of Obese Adults in the US, International Society for Quality of Life Research (ISOQOL), 2005.
108. Sullivan PW, Ghushchyan V, **Wu EQ**. Systematic Differences in Subjective vs. Societal Preferences, International Society for Quality of Life Research (ISOQOL), 2005.
109. **Wu EQ**, Xie J, Sullivan PW. Employment and Income Associated with Obesity and Overweight in the US, North American Association for the Study of Obesity (NAASO), 2005.
110. Colice G, Crivera C, Varghese S, Faruqi R, **Wu EQ**, Birnbaum H, Daher M, Marynchenko MB. Healthcare Costs of Patients with Persistent Asthma, Academy of Managed Care Pharmacy (AMCP), 2005.
111. Rousculp MD, Sasser AC, Birnbaum HG, Moyneur E, **Wu EQ**, Mallet D, Marcus R. Validation of a Budget Impact Model in Predicting First-Year Use of a New Osteoporosis Therapy, Academy of Managed Care Pharmacy (AMCP), 2005.
112. **Wu EQ**, Birnbaum H, Cifaldi M, Kang Y, Colice GL. Acute Exacerbation of Chronic Bronchitis (AECB) Treatment Effectiveness: Comparison of Macrolides to Fluoroquinolones, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2005.
113. **Wu EQ**, Birnbaum HG, Aggarwal J, Moulis M. The economic burden of schizophrenia in the United States in 2002, International Society for Pharmacoeconomics & Outcomes Research (ISPOR) European, 2005.
114. **Wu EQ**, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J. Using claims data to estimate the annual prevalence of schizophrenia in the United States, 2002, International Society for Pharmacoeconomics & Outcomes Research (ISPOR) European, 2005.

115. **Wu EQ**, Birnbaum H, Parece A, Kang Y, Mareva MN, Taitel H, Interstitial Cystitis Costs. Treatment and Comorbidities in an Employed Population, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2005.
116. **Wu EQ**, Birnbaum H, Kessler R, Shi L, Ball D. Economic Burden of Lost Productivity due to Schizophrenia in the United States: 2002, American Psychiatric Association (APA), 2005.
117. Ronald KC, Birnbaum H, Demler O, Falloon L, Gaggon E, Guyer M, Howes M, Kendler KS, Shi L, **Wu EQ**, Walters E. Prevalence and Correlates of Nonaffective Psychosis: Results from NCS-R, Society of Biological Psychiatry (SOBP), 2005.
118. **Wu EQ**, Birnbaum H, Cremieux P, Carpenter S, Borys N, Babich J. Comparison of Alternative Strategies for the Diagnosis of Acute Cardiac Ischemia in Emergency Departments: Standard of Care versus BMIPP, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2005.
119. **Wu EQ**, Birnbaum H, Kessler R, Beaulieu N, Daher M, Aggarwal J, Svanum H, Shi L. Direct Health Care Costs of Schizophrenia in the United States: 2002, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2005.
120. **Wu EQ**, Birnbaum H, Aggarwal J, Moulis M. Estimating Annual US Prevalence Rate of Schizophrenia in 2002, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2005.
121. Sasser A, Rousculp MD, Birnbaum H, Moyneur E, **Wu EQ**. Using A Budget Impact Model to Predict First-Year Use of A New Osteoporosis Therapy, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2005.
122. **Wu EQ**, Birnbaum H, Cifaldi M, Colice G, Kang Y. Development of a COPD Severity Score in Claims Database, International Society for Pharmacoeconomics & Outcomes Research (ISPOR) European, 2004.
123. **Wu EQ**, Birnbaum H, Greenberg P, Huang Z, Kessler R, Parece A, Victor T. Drug Treatment Patterns of Bipolar Disorder and Associated Costs, National Institute of Mental Health's (NIMH) New Clinical Drug Evaluation Unit (NCDEU) meeting, 2004.
124. **Wu EQ**, Birnbaum H, Mareva M, Le TK, Rosen A, Robinson R. Cost-Effectiveness of Duloxetine versus Routine Treatment for Painful Diabetic Neuropathy in a Randomized Trial from a Societal Perspective, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2004.
125. Parece A, **Wu EQ**, Birnbaum H, Greenberg P, Huang Z, Victor T, Kessler RC. Comorbidities and Cost Associated with Bipolar Disorder, American Public Health Association's (APHA), 2004.
126. **Wu EQ**, Howard BG, Mareva MN. Cost and Comorbidities Associated with Atrial Fibrillation, NASPE - Heart Rhythm Society, 2004.
127. **Wu EQ**, Birnbaum HG, Milena M. Cost and Comorbidities Associated with Atrial Fibrillation by Different Age Groups, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2004.
128. Parece A, **Wu EQ**, Birnbaum HG, Greenberg P, Huang Z, Victor T, Kessler RC. Cost and Comorbidities Associated with Bipolar Disorder, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2004.
129. **Wu EQ**, Birnbaum HG, Greenberg P, Kessler RC, Huang Z, Victor T. Drug Treatment Patterns of Bipolar Disorder and Associated Costs, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2004.
130. **Wu EQ**, Johnson KA, Nichol MB. Assessing the Cost Implication of Combined Pharmacotherapy in the Long Term Management of Asthma, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2003.

131. **Wu EQ**, Johnson KA, Nichol MB. Instrument Strength and Performance of a Parametric Latent Index Model in Estimating Average Treatment Effect (ATE), International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2003.
132. **Wu EQ**, Nichol MB, Johnson KA. Performance of Two Conditional Expectation Methods under Unobserved Selection Bias, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2003.
133. Chaikledkaew U, **Wu EQ**, Johnson KA. A Methodology To Identify High-Risk Patients With Diabetes In The California Medicaid Population (Medi-Cal), International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2003.
134. Chaikledkaew U, **Wu EQ**, Johnson KA. Factors Associated With High-Risk Diabetic Patients In The California Medicaid Populations (Medi-Cal), International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2003.
135. Rosberg J, Oster EF, **Wu EQ**, Fastenau J, Piech CT. Dose Conversion Of Erythropoietic Agents In Chemotherapy-Induced Anemia: A Meta-Analysis, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2003.
136. Barlev A, Globe D, **Wu EQ**, Yu W, Johnson K. "The Comparison Of Different Methods For Determining The Impact Of Migraine Prophylaxis On Costs," 2003, International Society for Pharmacoeconomics and Outcome Research (ISPOR) 8th Annual International Meeting.
137. **Wu EQ**, Hay J. Survival and Nursing Home Free Survival (NHFS) of Alzheimer's Disease (AD) Patients, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2001.
138. **Wu EQ**, Hay J. Alternative Management Strategies for Dyspepsia, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2001.
139. **Wu EQ**, Hay JW. Comparative Econometric Models of Medical Costs, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2000.
140. Burk C, Nichol MB, **Wu EQ**, Gilderman A, Salas J. The Impact of An Over-The-Counter Migraine Medication on Quality of Life, International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2000.

Other Invited Presentations

1. "North American Pharmaceutical and Dietary Supplement Market and Regulation," Expert Panel Report, Tianjin Economic and Trade Commission, and Food and Drug Administration, China, 2007
2. "Dealing with Selection Bias in Health Economics," Health Economics Department, Peking University, 2004, 1st Author
3. "Treatment Effects and Selection Bias in Retrospective Studies," University of Southern California, 2002, 1st Author
4. "How to launch a Pharmaceutical Product in Foreign Market: an example in Korea," University of Southern California, 2002, 1st Author
5. "Genetically Engineered Crops: Regulation, Market, and Trends," University of Southern California, 2002, 1st Author
6. "Hatch-Waxman Act and Generic Drug Application, Regulation and Legal Issues," University of Southern California, 2001, 1st Author

7. "Advance in Panel Data Analysis," University of Southern California, 2001, 1st Author
8. "Selection Bias and Treatment Effect, an introduction to microeconometrics theory," University of Southern California, 2001, 1st Author
9. "Marketing Considerations for a New Wound Dressing," University of Southern California, 2001, 1st Author
10. "Measuring Utilities in Health Care: HUI and others," University of Southern California, 2001, 1st Author
11. "How to Conduct Focus Group Study," University of Southern California, 2000, 1st Author
12. "Introduction of the Health Care Market in the United States," US-China Business Institute, 2000, 1st Author
13. "Missing Data Imputation," Health Economics Department, Amgen Inc., 1999, 1st Author

"INTRODUCTION OF SURVIVAL ANALYSIS," UNIVERSITY OF SOUTHERN CALIFORNIA, 1998, 1ST AUTHOR ADVISORY BOARD POSITIONS AND PROFESSIONAL ASSOCIATION MEMBERSHIPS

- 2009- Expert Panel, China Health Economic Evaluation Center, Chinese Medical Doctor Association
- 2009- Review committee, China's national formulary user guideline
- 2009- Adjunct Professor, Nankai University, School of Pharmacy, China
- 2009- Advisory Board, Tianjin Technology and Development Center, China
- 2007 Advisory Board, Daiichi Sankyo Inc.
- 2001- Member, International Society of Pharmacoeconomics and Outcome Research (ISPOR)
- 2003- Member, Chinese Economists Society (CES)
- 2005-06 Member, Society of Industry Leaders (SIL)
- 2002-03 Member, International AIDS Society (IAS)
- 2002 Member, Drug Information Association (DIA)